Zhang Xiaoyan, Lu Qiaoyuan, Guo Xiangjie, Cao Wuteng, Zhang Hongmei, Yu Tao, Li Xiaoting, Guan Zhen, Li Xueping, Sun Ruijia, Sun Yingshi
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Department of Forensic Medicine, Shanxi Medical University, Taiyuan 030001, China.
Chin J Cancer Res. 2021 Oct 31;33(5):606-615. doi: 10.21147/j.issn.1000-9604.2021.05.07.
To forward the magnetic resonance imaging (MRI) based distance between the deepest tumor invasion and mesorectal fascia (DMRF), and to explore its prognosis differentiation value in cT3 stage rectal cancer with comparison of cT3 substage.
This was a retrospective, multicenter cohort study including cT3 rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by radical surgery from January 2013 to September 2014. DMRF and cT3 substage were evaluated from baseline MRI. The cutoff of DMRF was determined by disease progression. Multivariate cox regression was used to test the prognostic values of baseline variables.
A total of 804 patients were included, of which 226 (28.1%) developed progression. A DMRF cutoff of 7 mm was chosen. DMRF category, the clock position of the deepest position of tumor invasion (CDTI) and extramural venous invasion (EMVI) were independent predictors for disease progression, and hazard ratios (HRs) were 0.26 [95% confidence interval (95% CI), 0.13-0.56], 1.88 (95% CI, 1.33-2.65) and 1.57 (95% CI, 1.13-2.18), respectively. cT3 substage was not a predictor for disease progression.
The measurement of DMRF value on baseline MRI can better distinguish cT3 rectal cancer prognosis rather than cT3 substage, and was recommended in clinical evaluation.
提出基于磁共振成像(MRI)测量的肿瘤最深浸润与直肠系膜筋膜(DMRF)之间的距离,并通过比较cT3亚分期探讨其在cT3期直肠癌中的预后判别价值。
这是一项回顾性多中心队列研究,纳入了2013年1月至2014年9月期间接受新辅助放化疗后行根治性手术的cT3期直肠癌患者。从基线MRI评估DMRF和cT3亚分期。DMRF的临界值由疾病进展情况确定。采用多变量cox回归检验基线变量的预后价值。
共纳入804例患者,其中226例(28.1%)出现疾病进展。选择DMRF临界值为7mm。DMRF分类、肿瘤浸润最深位置的时钟位置(CDTI)和壁外静脉侵犯(EMVI)是疾病进展的独立预测因素,风险比(HRs)分别为0.26[95%置信区间(95%CI),0.13 - 0.56]、1.88(95%CI,1.33 - 2.65)和1.57(95%CI,1.13 - 2.18)。cT3亚分期不是疾病进展的预测因素。
在基线MRI上测量DMRF值比cT3亚分期能更好地判别cT3期直肠癌的预后,建议在临床评估中采用。